| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
188 |
| Employees |
1,200 |
| Revenues (TTM) (Millions $) |
2,300 |
| Net Income (TTM) (Millions $) |
-750 |
| Cash Flow (TTM) (Millions $) |
61 |
| Capital Exp. (TTM) (Millions $) |
161 |
Business Description
Seagen Inc., formerly known as Seattle Genetics, is an American biotechnology company founded in 1998 and headquartered in Bothell, Washington.
The company's primary focus is on developing and commercializing innovative, targeted therapies for the treatment of cancer and other challenging diseases.
Seagen's primary product is ADCETRIS (brentuximab vedotin), which is an antibody-drug conjugate (ADC) that delivers the chemotherapy drug directly to cancer cells.
ADCETRIS has been approved for the treatment of several different types of cancer, including Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and primary cutaneous anaplastic large cell lymphoma.
Seagen has also developed several other ADCs that are in various stages of clinical development.
These include tucatinib, which is in Phase 3 clinical trials for the treatment of HER2-positive breast cancer; ladiratuzumab vedotin, which is in Phase 2 trials for the treatment of triple-negative breast cancer; and datopotamab deruxtecan, which is in Phase 1 trials for the treatment of various solid tumors.
Aside from ADCs, Seagen has also developed proprietary technologies for antibody-drug conjugate production, including its proprietary linker and cytotoxic payload technologies that enable a higher therapeutic index and greater specificity for tumor cells.
Seagen has partnerships with various pharmaceutical companies, including Takeda Pharmaceutical Company, Astellas Pharma, and Merck.
The company has also received funding from the National Cancer Institute and various venture capital firms.
In conclusion, Seagen Inc.
is a biotechnology company that specializes in the development and commercialization of targeted therapies for cancer and other diseases, with a primary focus on antibody-drug conjugates.
The company's flagship product is ADCETRIS, and it has several other products in various stages of clinical development.
Its proprietary technologies for ADC production give it a unique advantage in the field, and it has partnerships and funding from various large pharmaceutical companies and organizations.
Company Address: 21823 30th Drive SE Bothell 98021 WA
Company Phone Number: 527-4000 Stock Exchange / Ticker: NASDAQ SGEN
|
%
1.11%